Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;100(6):1334-1335.
doi: 10.1016/j.kint.2021.10.006. Epub 2021 Oct 14.

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost

Tamara Davidovic  1 , Judith Schimpf  1 , Armin Abbassi-Nik  1 , Richard Stockinger  2 , Hannelore Sprenger-Mähr  1 , Karl Lhotta  3 , Emanuel Zitt  4
Affiliations

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost

Tamara Davidovic et al. Kidney Int. 2021 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–spike IgG concentration after vaccination with the mRNA-BNT162b2 vaccine (Pfizer–BioNTech) in hemodialyis patients. Box-and-whisker plots including individual data points are displayed. The threshold for seropositivity (≥33.8 binding antibody units [BAUs]/ml) is represented by the dashed line.
See this image and copyright information in PMC

References

    1. Carr E.J., Kronbichler A., Graham-Brown M., et al. Review of early immune response to SARS-CoV-2 vaccination among patients with CKD. Kidney Int Rep. 2021;6:2292–2304. - PMC - PubMed
    1. Zitt E., Davidovic T., Schimpf J., et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021;12:704773. - PMC - PubMed
    1. Banham G.D., Godlee A., Faustini S.E., et al. Hemodialysis patients make long-lived antibodies against SARS-CoV-2 that may be associated with reduced reinfection. J Am Soc Nephrol. 2021;32:2140–2142. - PMC - PubMed
    1. Tan C.W., Chia W.N., Qin X., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073–1078. - PubMed
    1. Blazquez-Navarro A., Safi L., Meister T.L., et al. Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients. Kidney Int. 2021;100:698–700. - PMC - PubMed